Table 1 Demographic, clinical and lung involvement characteristics of 46 scleroderma patients
From: β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up
All scleroderma Patients | 24 scleroderma pts with alveolitis | 22 scleroderma pts without alveolitis | |
|---|---|---|---|
Age (y, mean ± SD) | 55.1 ± 14 | 60.6 ± 11.7* | 49 ± 14 |
Disease duration (y, mean ± SD)** | 6.1 ± 6.2 | 5.4 ± 5.4 | 6.9 ± 7.1 |
Early disease (<3 y) n (%) | 21 (45.6%) | 12 (50%) | 9 (40.9%) |
Female n (%) | 36 (78.3%) | 20 (83.3%) | 16 (72.7%) |
dSSc n (%) | 15 (32.6%) | 7 (29.2%) | 8 (36.4%) |
AntiScl70 n (%) | 28 (60.9%) | 16 (66.7%) | 12 (54.5%) |
Anticentromere n (%) | 5 (10.9%) | 2 (8.3%) | 3 (12.6%) |
Antiribonucleoprotein n (%) | 3 (6.5%) | 1 (4.2%) | 2 (9.1%) |
Antinucleolus n (%) | 3 (6.5%) | 2 (8.3%) | 1 (4.5%) |
FVC% (mean ± SD) | 93.1 ± 20.9 | 89.2 ± 23.1 | 97.3 ± 17.8 |
DLCO% (mean ± SD) | 52.3 ± 14.8 | 48.9 ± 17.1 | 56 ± 11.2 |
Restrictive lung disease n (%) | 14 (30.4%) | 11 (45.8%)* | 3 (13.6%) |
Ground glass score (mean ± SD) | 7.8 ± 5.6 | 9.7 ± 5.8* | 5.6 ± 4.6 |
Interstitial score (mean ± SD) | 6.3 ± 2.7 | 6.6 ± 2.8 | 5.9 ± 2.6 |
Alveolitis on BALF | 24 (52.2%) | / | / |
PASP (mmHg; mean ± SD) | 27.8 ± 5.7 | 30.8 ± 5.7* | 25.1 ± 4.2 |
HPAP n (%) | 5 (10.9%) | 5 (20.8%)* | 0 |
Treatment n (%) | 12 (26.1%) | 12 (50.0%) | 0 |
Smokers n (%) | 6 (13%) | 4 (16.7%) | 2 (9.1%) |